Shares of Moderna rose 4.36% to $130.59 at 10:48 EST on Thursday, following last session’s upward trend. NASDAQ Composite is rising 0.39% to $13,509.92, after two sequential sessions in a row of gains. This seems, at the moment, a somewhat positive trend exchanging session today.

Moderna’s last close was $125.14, 36.69% below its 52-week high of $178.50.

News about Moderna today

Philippines nears Moderna deal as covid infections rise outside manila. According to today’s article on Bloomberg Quint, "The Philippines is nearing a deal with Moderna Inc. for as much as 20 million vaccine doses as it monitors a post-holiday spike in coronavirus cases outside Manila.", "A supply deal with Moderna will likely be finished this month, Carlito Galvez, who leads the vaccination program, said in a televised briefing on Thursday. "

Moderna says first participant dosed in phase 1/2 study of Covid-19 vaccine in Japan. According to today’s article on Business Insider, "Participants will be followed through 12 months after the second vaccination, Moderna said. ."

Moderna’s Sales

Moderna’s sales growth is 1986.4% for the ongoing quarter and 19117.5% for the next. The company’s growth estimates for the current quarter and the next is 18.9% and 660%, respectively.

Moderna’s Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Volatility

Moderna’s last day, last week, and last month’s average volatility was a positive 0.10%, a positive 0.10%, and a negative 0.70%, respectively.

Moderna’s last day, last week, and last month’s high and low average amplitude percentage was 3.08%, 5.11%, and 7.97%, respectively.

Moderna’s Stock Yearly Top and Bottom Value

Moderna’s stock is valued at $130.59 at 10:48 EST, way below its 52-week high of $178.50 and way higher than its 52-week low of $17.91.

Moderna’s Moving Average

Moderna’s value is under its 50-day moving average of $132.56 and way above its 200-day moving average of $88.82.

Previous days news about Moderna

Moderna aiding California inquiry into allergic reactions. According to Bloomberg Quint on Tuesday, 19 January, "Of those, 964,900 doses already have been distributed to about 1,700 vaccination sites in 37 states, Moderna said. ", "This investigation is still ongoing and Moderna is working closely" with the U.S. Food and Drug Administration and CDC "to understand the clinical cases and whether the broad pause in use of the lot is warranted," the company said in a statement."

Moderna CEO expects 100 million vaccine doses by end of March. According to The Wall Street Journal on Tuesday, 19 January, "Chief Executive Stéphane Bancel said Tuesday that Moderna plans to deliver 100 million doses of its shot, which requires two doses per person, for use in the U.S. by the end of March, with additional doses to follow. "

LEAVE A REPLY

Please enter your comment!
Please enter your name here